International: +1-347-960-6455
Mitochondrial-Based Therapeutics Pipeline to Observe Significant Growth in the Coming Years due to Booming Strategic Developments

According to a new research report Mitochondrial-Based Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, mitochondrial-based therapeutics pipeline currently exhibits a burgeoning pipeline with 27 drug candidates.

Mitochondrial-Based Therapeutics Pipeline Insights

Mitochondria generate adenosine tri-phosphate (ATP) through oxidative phosphorylation, and also plays a key role in apoptosis. Mitochondrial therapeutic development is focused on diseases, which are caused by mutations in mitochondrial deoxyribonucleic acid (DNA) or in nuclear gene encoding mitochondrial protein.

Mitochondrial dysfunction contributes to the pathology of many common disorders, such as neurodegeneration, metabolic disease, heart failure, and ischemic-reperfusion injury. Therefore, several strategies are aimed to therapeutically restore mitochondrial function and hence, smaller number of agents have entered in clinical trials for the development of mitochondrial based therapeutics drugs. The report states that positive clinical trial results and technological advancements are the major factors driving the growth of the mitochondrial-based therapeutics pipeline.

Insights into Pipeline Segments

Most of the mitochondrial-based therapeutics drugs are administered through oral route of administration. The intravenous route is the second most common route of administration adopted for administering these drugs, as it is easy to use, improves medication adherence, and ensures high degree of versatility and control.

Increasing Strategic Developments are Expected to Contribute to the Growth of the Mitochondrial-Based Therapeutics Pipeline

Various companies are investing in the development of mitochondrial-based therapeutics, and also aim to expand their product portfolio in near future. For instance, in August 2019, Zogenix Inc. acquired Modis Therapeutics Inc. This acquisition aimed to advance Zogenix’s rare disease portfolio of drugs. Through this acquisition, Zogenix Inc. gained license to develop and commercialize drug candidate, MT1621, which is an investigational deoxynucleoside substrate enhancement therapy, for the treatment of mtDNA depletion disorder.

Surge in the Number of Designations Granted Behold the Growth of the Mitochondrial-Based Therapeutics Pipeline

It has been observed that regulatory bodies are increasingly granting designations to mitochondrial-based therapeutics drugs, in order to pace up the development process of clinical trials. For instance, Modis Therapeutics Inc.’s drug candidate, MT1621, received Breakthrough Therapy Designation by the USFDA in 2019; Orphan Drug Designation by the USFDA and EMA; and PRIority Medicines (PRIME) designation by EMA in 2018, for the treatment of TK2 deficiency.

Browse report overview with detailed TOC on "Mitochondrial-Based Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:

Other than the companies mentioned above, Stealth BioTherapeutics Inc. and CohBar Inc., are also engaged in the development of mitochondrial-based therapeutics.

Mitochondrial-Based Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration

The report comprises detailed pipeline analysis of mitochondrial-based therapeutics that are being developed for the treatment of various diseases. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the development of mitochondrial-based therapeutics. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin associated with mitochondria.